The poor clinical outcome could also be due to the use of tumor antigens overexpressed or present in other tissues (NY-ESO-1, MUC1, MAGEA3, MART1, HER2) and the persistence of an immunosuppressive environment that would prevent the activity of DCs once entering the TME. This evidence concerns the gene MAGEA3 and neoplasm.